Table 1.
Patient’s neo-epitopes to which T cell reactivity was detected.
| Patient | % Tumor | # Mut | # SLP | # SSP | Genes | Mut cDNA | Mut a.a. | % Mut (WES) | Peptide | Peptide ID |
|---|---|---|---|---|---|---|---|---|---|---|
| NIC3 | 21 | 21 | 24 | 47 | PARVA | c.328C>G | p.P110R | 11 | NLPLSPIPFELDREDTMLEENEVRT | L01 |
| G3BP1 | c.244G>A | p.A82T | 11 | NCHTKIRHVDAHTTLNDGVVVQVMG | L13 | |||||
| G3BP1 | c.244G>A | p.A82T | 11 | IRHVDAHTTL | S13-1 | |||||
| NIC4 | 48 | 30 | 39 | 46 | ACTR10 | c.638G>A | p.R213H | 15 | SVPEGVLEDIKAHTCFVSDLKRGLK | L06 |
| RAE1 | c.1106A>G | p.X369W | 13 | WWLETLAQPELFLSTLPHLCTNLGP | L20-2 | |||||
| PDP1 | c.1024C>T | p.R342W | 45 | PKSEAKSVVKQDWLLGLLMPFRAFG | L29 | |||||
| PDP1 | c.1024C>T | p.R342W | 45 | SEAKSVVKQDW | S29-1 | |||||
| PDP1 | c.1024C>T | p.R342W | 45 | SEAKSVVKQDWL | S29-2 | |||||
| NIC5 | 72 | 49 | 71 | 94 | – | – | – | – | – | – |
| NIC6 | 79 | 23 | 24 | 32 | – | – | – | – | – | – |
| NIC7 | 78 | 33 | 44 | 70 | – | – | – | – | – | – |
| NIC15 | 43 | 15 | 15 | 108 | QRICH1 | c.1054C>A | p.V352F | 14 | VHVSGSPTALAAFKLEDDKEKMVGT | L11 |
| NIC17 | 51 | 45 | 47 | 60 | – | – | – | – | – | – |
% Tumor tumor purity, Mut mutation, SLP synthetic long peptides, SSP synthetic short peptides, WES reads in whole-exome sequencing.